Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine
Daiichi Sankyo (OTC:DSKYF) (OTC:DSNKY) has filed for marketing approval of DS-5670 to the regulatory authorities in Japan. DS-5670 is an mRNA…
AstraZeneca – Daiichi Sankyo’s Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
The European Commission has approved AstraZeneca Plc (NASDAQ:AZN) – Daiichi Sankyo’s (OTC:DSKYF) (OTC:DSNKY) Enhertu (trastuzumab deruxtecan) for advanced HER2-positive gastric or gastroesophageal junction…
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
AstraZeneca Plc (NASDAQ:AZN) reported initial data from the TROPION-PanTumor01 Phase 1 trial of datopotamab deruxtecan (Dato-DXd). The data showed encouraging and…
AstraZeneca-Daiichi Sankyo’s Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer
AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo (OTC:DSNKY) (OTC:DSKYF) shared updated data from the DESTINY-Breast03 Phase 3 trial evaluating Enhertu versus trastuzumab emtansine…
Daiichi Sankyo Q2 Sales ¥327.50B Up From ¥280.30B YoY. The Company Reports Net Profit Of ¥39.5B Up From ¥18.9B YoY
Daiichi Sankyo (OTC:DSNKY) reported ¥327.50 billion in sales this quarter. This is a 16.84 percent increase over sales of ¥280.30 billion in the same period last year.
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
On Tuesday, the FDA released briefing documents related to Spectrum Pharmaceutical Inc’s (NASDAQ:SPPI) application for poziotinib for treating patients with previously treated…
This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says
HC Wainwright initiated coverage on Rain Therapeutics Inc (NASDAQ:RAIN), with a price target of $10 with a Buy rating. With an upside…
Daiichi-AstraZeneca’s Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
The FDA has approved Daiichi Sankyo (OTC:DSNKY) and AstraZeneca plc’s (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic non-small cell lung cancer (NSCLC)…
AstraZeneca’s Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
AstraZeneca Plc (NASDAQ:AZN) reported initial results from the TROPION-Lung02 phase 1b trial showing that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab…
The Daily Biotech Pulse: FDA Tentatively Approves Avadel’s Narcolepsy Drug, European Approval Broadens AstraZeneca’s Enhertu in Breast Cancer, Pharma Giants’ Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: